Literature DB >> 11895930

Beta-chemokines are induced by Mycobacterium tuberculosis and inhibit its growth.

Jussi J Saukkonen1, Beth Bazydlo, Michael Thomas, Robert M Strieter, Joseph Keane, Hardy Kornfeld.   

Abstract

Chemokines (CK) are potent leukocyte activators and chemoattractants and aid in granuloma formation, functions critical for the immune response to Mycobacterium tuberculosis. We hypothesized that infection of alveolar macrophages (AM) with different strains of M. tuberculosis elicits distinct profiles of CK, which could be altered by human immunodeficiency virus (HIV) infection. RANTES, macrophage inflammatory protein-1 alpha (MIP-1 alpha), and MIP-1 beta were the major beta-CK produced in response to M. tuberculosis infection. Virulent M. tuberculosis (H37Rv) induced significantly less MIP-1 alpha than did the avirulent strain (H37Ra), while MIP-1 beta and RANTES production was comparable for both strains. MIP-1 alpha and MIP-1 beta were induced by the membrane, but not cytosolic, fraction of M. tuberculosis. M. tuberculosis-induced CK secretion was partly dependent on tumor necrosis factor alpha (TNF-alpha). AM from HIV-infected individuals produced less TNF-alpha and MIP-1 beta than did normal AM in response to either M. tuberculosis strain. We tested the functional significance of decreased beta-CK secretion by examining the ability of beta-CK to suppress intracellular growth of M. tuberculosis. MIP-1 beta and RANTES suppressed intracellular growth of M. tuberculosis two- to threefold, a novel finding. Thus, beta-CK contribute to the innate immune response to M. tuberculosis infection, and their diminution may promote the intracellular survival of M. tuberculosis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11895930      PMCID: PMC127823          DOI: 10.1128/IAI.70.4.1684-1693.2002

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  35 in total

1.  CXC chemokines IP-10 and mig expression and direct migration of pulmonary CD8+/CXCR3+ T cells in the lungs of patients with HIV infection and T-cell alveolitis.

Authors:  C Agostini; M Facco; M Siviero; D Carollo; S Galvan; A M Cattelan; R Zambello; L Trentin; G Semenzato
Journal:  Am J Respir Crit Care Med       Date:  2000-10       Impact factor: 21.405

2.  Macrophage inflammatory protein 1 modulates macrophage function.

Authors:  T J Fahey; K J Tracey; P Tekamp-Olson; L S Cousens; W G Jones; G T Shires; A Cerami; B Sherry
Journal:  J Immunol       Date:  1992-05-01       Impact factor: 5.422

3.  Decrease in cytokine production by HIV-infected macrophages in response to LPS-mediated activation.

Authors:  W P Tsai; K Hirose; P L Nara; Y D Kuang; S Conley; B Q Li; H F Kung; K Matsushima
Journal:  Lymphokine Cytokine Res       Date:  1991-12

Review 4.  Bronchoalveolar lavage constituents in healthy individuals, idiopathic pulmonary fibrosis, and selected comparison groups. The BAL Cooperative Group Steering Committee.

Authors: 
Journal:  Am Rev Respir Dis       Date:  1990-05

5.  The role of fiberoptic bronchoscopy for diagnosis of pulmonary tuberculosis in patients at risk for AIDS.

Authors:  A M Miro; E Gibilara; S Powell; S L Kamholz
Journal:  Chest       Date:  1992-05       Impact factor: 9.410

6.  Clinical presentation and outcome of patients with HIV infection and tuberculosis caused by multiple-drug-resistant bacilli.

Authors:  M A Fischl; G L Daikos; R B Uttamchandani; R B Poblete; J N Moreno; R R Reyes; A M Boota; L M Thompson; T J Cleary; S A Oldham
Journal:  Ann Intern Med       Date:  1992-08-01       Impact factor: 25.391

Review 7.  Macrophages and tuberculosis.

Authors:  M J Fenton
Journal:  Curr Opin Hematol       Date:  1998-01       Impact factor: 3.284

8.  A sensitive ELISA for the detection of human monocyte chemoattractant protein-1 (MCP-1).

Authors:  H L Evanoff; M D Burdick; S A Moore; S L Kunkel; R M Strieter
Journal:  Immunol Invest       Date:  1992-02       Impact factor: 3.657

9.  Mononuclear cell adherence induces neutrophil chemotactic factor/interleukin-8 gene expression.

Authors:  K Kasahara; R M Strieter; S W Chensue; T J Standiford; S L Kunkel
Journal:  J Leukoc Biol       Date:  1991-09       Impact factor: 4.962

10.  ICAM-1-independent lymphocyte transmigration across high endothelium: differential up-regulation by interferon gamma, tumor necrosis factor-alpha and interleukin 1 beta.

Authors:  M J May; A Ager
Journal:  Eur J Immunol       Date:  1992-01       Impact factor: 5.532

View more
  45 in total

1.  The Mycobacterium tuberculosis stress response factor SigH is required for bacterial burden as well as immunopathology in primate lungs.

Authors:  Smriti Mehra; Nadia A Golden; Kerstan Stuckey; Peter J Didier; Lara A Doyle; Kasi E Russell-Lodrigue; Chie Sugimoto; Atsuhiko Hasegawa; Satheesh K Sivasubramani; Chad J Roy; Xavier Alvarez; Marcelo J Kuroda; James L Blanchard; Andrew A Lackner; Deepak Kaushal
Journal:  J Infect Dis       Date:  2012-03-07       Impact factor: 5.226

2.  Tumor necrosis factor neutralization results in disseminated disease in acute and latent Mycobacterium tuberculosis infection with normal granuloma structure in a cynomolgus macaque model.

Authors:  Philana Ling Lin; Amy Myers; Le'Kneitah Smith; Carolyn Bigbee; Matthew Bigbee; Carl Fuhrman; Heather Grieser; Ion Chiosea; Nikolai N Voitenek; Saverio V Capuano; Edwin Klein; JoAnne L Flynn
Journal:  Arthritis Rheum       Date:  2010-02

Review 3.  Striking the right immunological balance prevents progression of tuberculosis.

Authors:  Shachi Pranjal Vyas; Ritobrata Goswami
Journal:  Inflamm Res       Date:  2017-07-15       Impact factor: 4.575

4.  Early events in Mycobacterium tuberculosis infection in cynomolgus macaques.

Authors:  Philana Ling Lin; Santosh Pawar; Amy Myers; Amarenda Pegu; Carl Fuhrman; Todd A Reinhart; Saverio V Capuano; Edwin Klein; Joanne L Flynn
Journal:  Infect Immun       Date:  2006-07       Impact factor: 3.441

Review 5.  HIV and tuberculosis: a deadly human syndemic.

Authors:  Candice K Kwan; Joel D Ernst
Journal:  Clin Microbiol Rev       Date:  2011-04       Impact factor: 26.132

6.  Interleukin-21 Regulates Natural Killer Cell Responses During Mycobacterium tuberculosis Infection.

Authors:  Padmaja Paidipally; Deepak Tripathi; Abhinav Van; Rajesh Kumar Radhakrishnan; Rohan Dhiman; Sambasivan Venkatasubramanian; Kamakshi P Devalraju; Amy R Tvinnereim; Vijaya Lakshmi Valluri; Ramakrishna Vankayalapati
Journal:  J Infect Dis       Date:  2018-03-28       Impact factor: 5.226

7.  Severe tuberculosis induces unbalanced up-regulation of gene networks and overexpression of IL-22, MIP-1alpha, CCL27, IP-10, CCR4, CCR5, CXCR3, PD1, PDL2, IL-3, IFN-beta, TIM1, and TLR2 but low antigen-specific cellular responses.

Authors:  Liyou Qiu; Dan Huang; Cystal Y Chen; Richard Wang; Ling Shen; Yun Shen; Robert Hunt; James Estep; Barton F Haynes; William R Jacobs; Norman Letvin; George Du; Zheng W Chen
Journal:  J Infect Dis       Date:  2008-11-15       Impact factor: 5.226

8.  Transcriptional reprogramming in nonhuman primate (rhesus macaque) tuberculosis granulomas.

Authors:  Smriti Mehra; Bapi Pahar; Noton K Dutta; Cecily N Conerly; Kathrine Philippi-Falkenstein; Xavier Alvarez; Deepak Kaushal
Journal:  PLoS One       Date:  2010-08-31       Impact factor: 3.240

9.  Vitamin D rescues impaired Mycobacterium tuberculosis-mediated tumor necrosis factor release in macrophages of HIV-seropositive individuals through an enhanced Toll-like receptor signaling pathway in vitro.

Authors:  Asha Anandaiah; Sanjeev Sinha; Medhavi Bole; Surendra K Sharma; Narendra Kumar; Kalpana Luthra; Xin Li; Xiuqin Zhou; Benjamin Nelson; Xinbing Han; Souvenir D Tachado; Naimish R Patel; Henry Koziel
Journal:  Infect Immun       Date:  2012-10-15       Impact factor: 3.441

10.  CCL2 responses to Mycobacterium tuberculosis are associated with disease severity in tuberculosis.

Authors:  Zahra Hasan; Jacqueline M Cliff; Hazel M Dockrell; Bushra Jamil; Muhammad Irfan; Mussarat Ashraf; Rabia Hussain
Journal:  PLoS One       Date:  2009-12-29       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.